Finch Therapeutics stockholders elect three Class I directors and ratify Deloitte as auditor

Finch Therapeutics Group, Inc.

36,785,341 shares (77.35% of outstanding) present at June 10, 2022 annual meeting.
Domenic Ferrante, Nicholas Haft, Samuel A. Hamood elected as Class I directors with >26.8M votes for each.
Ratification of Deloitte & Touche as auditor for FY2022 approved: 36,759,831 for, 20,585 against.
Broker non-votes of 7,987,710 on director election; none on auditor ratification.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.